Wyeth Pharmaceuticals

vorige Seite Seite 1 von 5 nächste Seite

Wyeth Receives Positive Opinion from European Regulators for its 13-valent Pneumococcal Candidate Vaccine for Infants and Young Children

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for …

OTE0007
25.09.2009 17:41
 

Jane Seymour Lends Support to Recognise the Hopes and Achievements of People Living With Rheumatoid Arthritis (RA)

- 26 Men and Women With RA From Across Europe Honoured as They Share Their Inspirational Stories

OTE0003
22.09.2009 09:10
 

Wyeth Presents Data from Five-Year Vertebral Fracture Prevention Study with Bazedoxifene

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announces findings from a placebo-controlled Phase 3 study of bazedoxifene 20 mg extended to five years, which indicated a significant reduction …

OTE0005
15.09.2009 14:08
 

Rheumatoid Arthritis (RA) Patients Taking Enbrel Keep Working for Longer

- Study Published in Rheumatology Underscores the Need for Early and Aggressive Treatment to Maintain Work Productivity

OTE0003
07.09.2009 08:10
 

Wyeth's Torisel Approved by European Commission for the Treatment of Relapsed and/or Refractory Mantle Cell Lymphoma

Wyeth Europa Ltd., a division of Wyeth (NYSE: WYE), announced today that the European Commission has approved the mTOR (mammalian target of rapamycin) inhibitor TORISEL(R) (temsirolimus) for the treatment …

OTE0004
27.08.2009 08:10
 

Studies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease

Elan Corporation, plc (NYSE: ELN) and Wyeth (NYSE: WYE) presented information this week at the Alzheimer Association 2009 International Conference on Alzheimer's Disease (ICAD 2009) from seven posters and …

OTE0009
14.07.2009 15:21
 

Wyeth's Prevenar 13* Receives First Approval

- Chile Grants First Approval of Prevenar 13 for the Prevention of Pneumococcal Disease in Infants and Children-

OTE0008
14.07.2009 14:11
 

Israel Adds Wyeth's 7-valent Pneumococcal Conjugate Vaccine (PCV7) to their National Immunisation Programme

- Prevenar Vaccine to Help Protect Children Against the Leading Vaccine-Preventable Cause of Death in Young Children Worldwide

OTE0005
14.07.2009 08:08
 

Wyeth Presents New Analyses of Data From Three Studies of ENBREL(R) at the European League Against Rheumatism (EULAR) Annual Meeting

- Two-year Data From COMET Study in Early Active Moderate-to-Severe Rheumatoid Arthritis Indicated Sustained Halt of Progressive Joint Damage

OTE0001
12.06.2009 10:22
 

New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease

New data from Phase 3 European clinical trials reinforce that Wyeth's (NYSE: WYE) investigational pneumococcal vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine, 13-valent [Adsorbed]), …

OTE0002
11.06.2009 13:09
 

Enbrel(R) Receives Positive European Recommendations for a New Plaque Psoriasis Treatment Regimen and New Pre-Filled Pen Delivery Device

- CHMP Recommends Approval of a Continuous Dosing Regimen Option for Enbrel In Plaque Psoriasis, and a New Pre-Filled Pen Delivery Device

OTE0004
04.06.2009 08:08
 

New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced preliminary data from two ongoing studies, one evaluating neratinib (HKI-272) in combination with trastuzumab (Herceptin(R), Roche) in …

OTE0013
29.05.2009 14:09
 

FDA Grants Priority Review Status to Prevnar 13 Marketing Application

-- Candidate vaccine designed to protect against the 13 most prevalent serotypes associated with pneumococcal disease --

OTE0009
07.05.2009 14:09
 

Wyeth's CONBRIZA Approved in the European Union for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the European Commission has granted marketing authorization for CONBRIZA(TM) (bazedoxifene), a selective estrogen receptor …

OTE0012
27.04.2009 15:14
 

New Partnerships Added to World Federation of Hemophilia Twinning Program

- Wyeth and Advocacy Community Mark Continued Commitment to Patient Care on World Hemophilia Day

OTE0010
17.04.2009 15:09
 
vorige Seite nächste Seite